ProPhase Labs (NASDAQ:PRPH – Get Free Report) and Adherex Technologies (NASDAQ:FENC – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.
Earnings and Valuation
This table compares ProPhase Labs and Adherex Technologies”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProPhase Labs | $5.05 million | 0.04 | -$53.36 million | ($2.25) | -0.00 |
| Adherex Technologies | $44.64 million | 8.65 | -$9.74 million | ($0.13) | -84.69 |
Volatility & Risk
ProPhase Labs has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
Institutional and Insider Ownership
9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by insiders. Comparatively, 10.7% of Adherex Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares ProPhase Labs and Adherex Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProPhase Labs | -825.01% | -482.05% | -88.90% |
| Adherex Technologies | -6.09% | -5.71% | -2.37% |
Analyst Ratings
This is a summary of recent ratings and price targets for ProPhase Labs and Adherex Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProPhase Labs | 1 | 0 | 0 | 0 | 1.00 |
| Adherex Technologies | 1 | 1 | 4 | 0 | 2.50 |
Adherex Technologies has a consensus target price of $17.00, indicating a potential upside of 54.41%. Given Adherex Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe Adherex Technologies is more favorable than ProPhase Labs.
Summary
Adherex Technologies beats ProPhase Labs on 13 of the 14 factors compared between the two stocks.
About ProPhase Labs
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
About Adherex Technologies
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.
